EU_Uro_Contents_A4 Contents 17/03/2010 11:57 Page 7
European
Urological Review
BRIEFINGS
European
• Prostate cancer
• Bladder cancer
Urological
• Renal cell carcinoma
• Testicular cancer
Review
• Overactive bladder
• Incontinence
Volume 3 Issue
Call for submissions
2
• Urogynaecology
• Premature ejaculation
• Male infertility

European Urological Review endeavours to support urologists in
their daily practice through peer-reviewed content, including original
European
Articles include:
Urological Review
contributions, commentaries, review articles and case studies. The
Transrectal Ultrasound-guided
Biopsy of the Prostate Volume 4
Issue 1
Marcel Hruza, Christian Stock and
Jens J Rassweiler
journal provides comprehensive discussion and analysis of the latest

Advances in the Understanding of the
Early Detection of Bladder Cancer
Levent N Türkeri and Ilker Tinay
medical advances and therapeutic options available to urologists to

Treatment of Testicular Cancer
Jan Oldenburg, Gustav Lehne,
help diagnose, treat and achieve better patient prognoses.
Mette Sprauten and Sophie D Fosså

The Doctor–Patient Relationship in Treatment of Benign
Overactive Bladder Management
Daniela Marschall-Kehrel Prostatic Hyperplasia in the
Geriatric Patient
Surgical Treatment of Female Stress Roberto Miano, Cosimo De
Join the debate
Urinary Incontinence Nunzio, Andrea Tubaro and
Giacomo Novara Anastasios Asimakopoulos

Defining Premature Ejaculation
Chris G McMahon Prostate Cancer Recurrence
After Radical Prostatectomy
With a focus on all aspects of urology, including practice management
Current Recommendations for Genetic
Morgan Rouprêt
Testing in Male Infertility
ww w .touchbriefings.com Frank Tüttelmann and Manuela Simoni
Update on Penile Cancer
and policy,
Niels M Graafland and
European Urological Review is always keen to hear from
Simon Horenblas
leading authorities wishing to discuss potential submissions and will Management Practices and
Newly Approved Treatments
give due consideration to all manuscripts submitted.
for Premature Ejaculation
Stefan Arver
Dietary Sensitivity of
Interstitial Cystitis –
Manuscripts can be submitted to the journal’s Editor, Amy Brewerton.
Bane and Opportunity
David J Klumpp and
Charles N Rudick
www.touchbriefings.com
To download the ‘Instructions to Authors’ information, please visit
www.touchbriefings.com
European Urological Review For further information, please contact
Touch Briefings Amy Brewerton
Saffron House, 6–10 Kirby Street, T: +44 (0) 20 7452 5008
amy.brewerton@touchbriefings.com
A new era
of convenience
the once-yearly implant
for prostate cancer
The Vantas implant is soft and flexible
(actual size 3.5cm x 3mm)
For further information
please visit: www.vantas.eu
ONCE-YEARLY
Abbreviated prescribing information
These patients should be considered for prophylactic treatment with anti-androgens. If spinal
cord compression or renal impairment occurs, the standard treatment for these complications
The Vantas
®
implant contains 50 mg of histrelin acetate with an average release of histrelin acetate should be initiated.
50 µg/24 hr. The recommended dose of Vantas
®
is one implant for 12 months. The Vantas implant is
inserted subcutaneously in the inner aspect of the upper arm.
Adverse effects: Like other LH-RH agonists, Vantas may cause gynaecomastia or impotence of
varying duration in some patients. It can be anticipated that long periods of medical castration in
Indication: Palliative treatment of advanced prostate cancer.
men will have effects on bone density. The most common adverse effects associated with Vantas in
Contraindications: Vantas is contraindicated in patients with hypersensitivity to histrelin or to any
the clinical trials were implant site reactions, the majority of which were reported as mild and
of the excipients in the implant, GnRH, GnRH agonists/analogues, or stearic acid. Anaphylactic
resolved within the first two weeks.
reactions to synthetic LH-RH or LH-RH agonists/analogues, have also been reported.
Insertion of an implant is a surgical procedure. Careful adherence to the recommended procedures for
Special warning and precautions: Like other LH-RH agonists, Vantas causes a transient increase
insertion and removal is recommended in order to reduce the risk of complications and implant expulsion.
in serum concentrations of testosterone during the first week of treatment. Patients may experience
a worsening of symptoms or onset of new symptoms, including joint pain, bone pain, neuropathy,
Marketing authorisation holder: Orion Corporation
haematuria, or ureteral or bladder outlet obstruction. Cases of ureteral obstruction and spinal cord
Corporate address: Orionintie 1 FI-02200 Espoo, Finland
Marketing authorisation holder:
Orion Corporation Orion Pharma
compression, which may lead to paralysis with or without fatal complications, have been reported
P.O.Box 65
in connection with LH-RH agonists. Patients with metastatic vertebral lesions and/or urinary tract For full product information see prescribing information.
02101 Espoo Finland obstruction should be closely observed during the first few weeks of therapy. For further information, please contact the local Orion Pharma office.
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68  |  Page 69  |  Page 70  |  Page 71  |  Page 72  |  Page 73  |  Page 74  |  Page 75  |  Page 76  |  Page 77  |  Page 78  |  Page 79  |  Page 80  |  Page 81  |  Page 82  |  Page 83  |  Page 84  |  Page 85  |  Page 86  |  Page 87  |  Page 88  |  Page 89  |  Page 90  |  Page 91  |  Page 92  |  Page 93  |  Page 94  |  Page 95  |  Page 96  |  Page 97  |  Page 98  |  Page 99  |  Page 100